



## CLINICAL COMPOUND OVERVIEW

Boehringer Ingelheim are taking on cancer through a dedicated commitment to delivering first-in-class cancer-cell directed therapies, innovative immuno-oncology strategies and smart combination approaches. Our goal is to achieve cancer breakthroughs that give hope to patients. Find out more about our oncology clinical trial programme and long-term research commitment:

COMPOUND/TARGET	LATEST DEVELOPMENT PHASE, BY FOCUS			
	Phase I	Phase II	Phase III	Approved
<b>Cancer cell-directed and immuno-oncology therapies</b>				
<b>Afatinib</b> EGFR (ErbB1); HER2 (ErbB2); ErbB3; ErbB4				NSCLC <sup>1</sup>
<b>Nintedanib</b> VEGFR; FGFR; PDGFR				NSCLC <sup>2</sup>
<b>Xentuzumab (BI 836845)</b> IGF ligands (IGF1; IGF2)	NSCLC <sup>3</sup> Breast cancer <sup>3,4</sup>	Breast cancer <sup>5</sup>		
<b>PD-1 inhibitor (BI 754091)</b>	Solid tumours <sup>6-12</sup>			
<b>LAG-3 inhibitor (BI 754111)</b>	Solid tumours <sup>8-10,12</sup>			
<b>VEGF/Ang2 inhibitor (BI 836880)</b>	Solid tumours <sup>6,13-15</sup>			
<b>BET inhibitor (BI 894999)</b>	Solid tumours <sup>16</sup>			
<b>SMAC mimetic (BI 891065)</b>	Solid tumours <sup>11</sup>			
<b>MDM2-p53 antagonist (BI 907828)</b>	Solid tumours <sup>12,17</sup>			
<b>LRP5/6 antagonist (BI 905677)</b>	Solid tumours <sup>18</sup>			
<b>LRP5 antagonist (BI 905681)</b>	Solid tumours <sup>19</sup>			
<b>SIRPα antagonist (BI 765063)</b>	Solid tumours <sup>20</sup>			
<b>SOS1::KRAS inhibitor (BI 1701963)</b>	Solid tumours <sup>21</sup>			
<b>mRNA cancer vaccine (BI 1361849)</b>	NSCLC <sup>22</sup>			
<b>KISIMA™ cancer vaccine (ATP-128)</b>	CRC <sup>23</sup>			
<b>STING agonist</b>	Solid tumours			
<b>TRAILR2/CDH17 antibody (BI 905711)</b>	Gastrointestinal cancers <sup>24</sup>			
<b>MEK inhibitor (in preparation)</b>				
<b>DLL3/CD3 bispecific antibody (in preparation)</b>				
<b>VSV-GP oncolytic virus platform (in preparation)</b>				

See next page for combination approaches



# CLINICAL COMPOUND OVERVIEW

COMPOUND/TARGET	LATEST DEVELOPMENT PHASE, BY FOCUS			
	Phase I	Phase II	Phase III	Approved
<b>Combination approaches</b>				
LAG-3 inhibitor (BI 754111) + PD-1 inhibitor (BI 754091)	Solid tumours <sup>8-10</sup>	Solid tumours <sup>25</sup>		
VEGF/Ang2 inhibitor (BI 836880) + PD-1 inhibitor (BI 754091)	NSCLC <sup>15</sup>			
SMAC mimetic (BI 891065) + PD-1 inhibitor (BI 754091)	Solid tumours <sup>11</sup>			
MDM2-p53 antagonist (BI 907828) + LAG-3 inhibitor (BI 754111) + PD-1 inhibitor (BI 754091)	Solid tumours <sup>12</sup>			
SIRPα antagonist (BI 765063) + PD-1 inhibitor (BI 754091)	Solid tumours <sup>20</sup>			
KISIMA™ cancer vaccine (ATP-128) + PD-1 inhibitor (BI 754091)	CRC <sup>23</sup>			

**Afatinib** is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib. Registration conditions differ internationally; please refer to locally approved prescribing information. **Nintedanib** is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please visit: <https://www.vargatef.com/countries>. Nintedanib is not approved in other oncology indications.

**Xentuzumab, BI 836880, BI 894999, BI 754091, BI 754111, BI 891065, BI 907828, BI 905677, BI 905681, BI 765063, BI 1361849, BI 1701963, KISIMA™ cancer vaccine (ATP-128), STING agonist, BI 905711, MEK inhibitor, DLL3/CD3 bispecific antibody and VSV-GP oncolytic virus platform** are investigational compounds and have not been approved. Their safety and efficacy have not been established.

Ang2, angiopoietin 2; BET, bromodomain and extra terminal motif; CD, cluster of differentiation; CDH17, cell anchor cadherin 17; CRC, colorectal cancer; DLL3, Delta-like 3; EGFR, epidermal growth factor receptor; ErbB, epidermal growth factor receptor tyrosine kinase family receptor; FGFR, fibroblast growth factor receptor; GP, glycoprotein; HER2, human epidermal growth factor receptor 2; IGF, insulin-like growth factor; KRAS, Kirsten rat sarcoma; LAG-3, lymphocyte activation gene 3 protein; LRP, lipoprotein receptor-related protein; MDM2, murine double minute 2 protein; MEK, mitogen-activated extracellular signal regulated kinase; mRNA, messenger ribonucleic acid; NSCLC, non-small-cell lung carcinoma; PD-1, programmed cell death protein-1; PDGFR, platelet-derived growth factor receptor; SIRPα, signal-regulatory protein alpha; SMAC, second mitochondria-derived activator of caspase; SOS1, Son of sevenless homolog 1; STING, small molecule agonist of the stimulator of interferon genes; TRAILR2, tumour necrosis factor-related apoptosis-inducing ligand receptor 2; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; VSV, vesicular stomatitis virus.

1. Prescribing Information: GIOTRIF®. [https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_en.pdf) (Accessed: March 2020); 2. Prescribing Information: VARGATEF®. [https://www.ema.europa.eu/en/documents/product-information/vargatef-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/vargatef-epar-product-information_en.pdf) (Accessed: March 2020); 3. ClinicalTrials.gov. NCT03099174. <https://clinicaltrials.gov/ct2/show/NCT03099174> (Accessed: March 2020); 4. ClinicalTrials.gov. NCT02123823. <https://clinicaltrials.gov/ct2/show/NCT02123823> (Accessed: March 2020); 5. ClinicalTrials.gov. NCT03659136. <https://clinicaltrials.gov/ct2/show/NCT03659136> (Accessed: March 2020); 6. ClinicalTrials.gov. NCT03468426. <https://clinicaltrials.gov/ct2/show/NCT03468426> (Accessed: March 2020); 7. ClinicalTrials.gov. NCT02952248. <https://clinicaltrials.gov/ct2/show/NCT02952248> (Accessed: March 2020); 8. ClinicalTrials.gov. NCT03156114. <https://clinicaltrials.gov/ct2/show/NCT03156114> (Accessed: March 2020); 9. ClinicalTrials.gov. NCT03780725. <https://clinicaltrials.gov/ct2/show/NCT03780725> (Accessed: March 2020); 10. ClinicalTrials.gov. NCT03433898. <https://clinicaltrials.gov/ct2/show/NCT03433898> (Accessed: March 2020); 11. ClinicalTrials.gov. NCT03166631. <https://clinicaltrials.gov/ct2/show/NCT03166631> (Accessed: March 2020); 12. ClinicalTrials.gov. NCT03964233. <https://clinicaltrials.gov/ct2/show/NCT03964233> (Accessed: March 2020); 13. ClinicalTrials.gov. NCT02674152. <https://clinicaltrials.gov/ct2/show/NCT02674152> (Accessed: March 2020); 14. ClinicalTrials.gov. NCT02689505. <https://clinicaltrials.gov/ct2/show/NCT02689505> (Accessed: March 2020); 15. ClinicalTrials.gov. NCT03468426. <https://clinicaltrials.gov/ct2/show/NCT03468426> (Accessed: March 2020); 16. ClinicalTrials.gov. NCT02516553. <https://clinicaltrials.gov/ct2/show/NCT02516553> (Accessed: March 2020); 17. ClinicalTrials.gov. NCT03449381. <https://clinicaltrials.gov/ct2/show/NCT03449381> (Accessed: March 2020); 18. ClinicalTrials.gov. NCT03604445. <https://clinicaltrials.gov/ct2/show/NCT03604445> (Accessed: March 2020); 19. ClinicalTrials.gov. NCT04147247. <https://clinicaltrials.gov/ct2/show/NCT04147247> (Accessed: March 2020); 20. ClinicalTrials.gov. NCT03990233. <https://clinicaltrials.gov/ct2/show/NCT03990233> (Accessed: March 2020); 21. ClinicalTrials.gov. NCT0411458. <https://clinicaltrials.gov/ct2/show/NCT0411458> (Accessed: March 2020); 22. ClinicalTrials.gov. NCT03164772. <https://clinicaltrials.gov/ct2/show/NCT03164772> (Accessed: March 2020); 23. ClinicalTrials.gov. NCT04046445. <https://clinicaltrials.gov/ct2/show/NCT04046445> (Accessed: March 2020); 24. ClinicalTrials.gov. NCT04137289. <https://clinicaltrials.gov/ct2/show/NCT04137289> (Accessed: March 2020); 25. ClinicalTrials.gov. NCT03697304. <https://clinicaltrials.gov/ct2/show/NCT03697304> (Accessed: March 2020).

© Boehringer Ingelheim International GmbH 2020. This document and its contents are the property of Boehringer Ingelheim (third party sources are indicated) and are, inter alia, protected by copyright law. Complete or partial passing on to third parties, as well as copying, reproduction, publication or any other use by third parties, is not permitted.